The Brief

Pfizer is expediting its efforts to delve into the growing obesity treatment field with a nearly $5 billion acquisition.

The company told the Associated Press Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera.

Does Pfizer currently have an obesity drug?

Dig deeper:

According to the Associated Press, Pfizer currently has no obesity treatments on the market but has some in clinical development.

Earlier this year, Pfizer told the AP that it was halting development of a potential once-daily pill treatment before it started late-stage testing, which is the most expensive phase of clinical development.

RELATED: Pharmacy firm cuts prices for popular weight-loss drug again

Metsera Inc. also doesn’t have obesity products on the market

See Full Page